Albany Molecular Research Inc., a drug discovery company that has moved into a new facility on the Buffalo Niagara Medical Campus, and HarkerBIO, a Buffalo-based startup company, have reached a collaborative, three-year agreement to jointly market their services to international pharmaceutical and biotech firms, the companies announced Monday.
Under the agreement, AMRI gains access to HarkerBIO technology that helps companies better understand the three-dimensional structures of diseases, while HarkerBIO’s customers benefit from AMRI’s global reach and its integrated drug-discovery platforms. Financial terms of the agreement were not disclosed.
AMRI, which is based in Albany, earlier this year opened a permanent office in the Conventus building on the Medical Campus, a project supported by funding from the Buffalo Billion economic-development initiative. State officials had said AMRI’s opening of a research facility in Buffalo would encourage alliances with local biotech companies.
HarkerBIO was founded in 2014 and grew out of technology developed at the Hauptman-Woodward Medical Research Institute, where the company is located. HarkerBIO is collaborating with the University at Buffalo’s Center for Computational Research and, as part of its participation in the Start-Up NY program, would add five jobs, doubling its workforce, and invest $500,000 in its new facility.